Leerink analyst Mani Foroohar lowered the firm’s price target on BridgeBio to $46 from $47 ahead of quarterly results to reflect recent disclosures and management commentary. The firm keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- BridgeBio initiated with an Outperform at Scotiabank
- BridgeBio Pharma call volume above normal and directionally bullish
- BridgeBio presenting results of Phase 3 study of acoramidis in ATTR-CM
- BridgeBio initiated with a Perform at Oppenheimer